FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年2月28日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 嘉濤（香港）控股有限公司 (於開曼群島註冊成立的有限公司) 呈交日期: 2026年3月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | 是 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02189 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 3,000,000,000 | HKD | | 0.01 | HKD | | 30,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 3,000,000,000 | HKD | | 0.01 | HKD | ...

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年1月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 嘉濤（香港）控股有限公司 (於開曼群島註冊成立的有限公司) 呈交日期: 2026年2月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02189 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 3,000,000,000 | HKD | | 0.01 HKD | | 30,000,000 | | 增加 / 減少 (-) | | | | | | HKD | | | | 本月底結存 | | | 3,000,000,000 | HKD | | 0.01 HKD | | 30,000,000 | 本月底 ...

Group 1 - The chairman and executive director of the company, Wei Shicheng, increased his stake in Jiatou (Hong Kong) Holdings (02189) by purchasing 128,000 shares at a price of HKD 0.445 per share, totaling HKD 56,960 [1] - Following this purchase, the total number of shares held by Wei Shicheng is approximately 655 million, representing a holding percentage of 65.53% [1] Group 2 - The transaction involves a related party, Wei Xiaoling [2]

Group 1 - The chairman and executive director of the company, Wei Shicheng, increased his stake in Jiatao (Hong Kong) Holdings by purchasing 128,000 shares at a price of HKD 0.445 per share, totaling HKD 56,960 [1] - After the purchase, the total number of shares held by Wei Shicheng is approximately 655 million, representing a holding percentage of 65.53% [1] Group 2 - The transaction involves a related party, Wei Xiaoling [2]

Group 1 - The chairman and CEO of the company, Wei Shicheng, increased his stake in Jiatou (Hong Kong) Holdings (02189) by purchasing 376,000 shares at a price of HKD 0.45 per share, totaling HKD 169,200 [1] - After the purchase, Wei Shicheng's total shareholding amounts to approximately 655 million shares, representing a holding percentage of 65.52% [1] - The transaction involves a related party, Wei Xiaoling [1]

Group 1 - The chairman and CEO of Jiatao (Hong Kong) Holdings, Wei Shicheng, increased his shareholding by purchasing 376,000 shares at a price of HKD 0.45 per share, totaling HKD 169,200 [1] - After the purchase, Wei Shicheng's total shareholding amounts to approximately 655 million shares, representing a 65.52% ownership stake in the company [1] - The transaction involves a related party, Wei Xiaoling [1]

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年12月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 嘉濤（香港）控股有限公司 (於開曼群島註冊成立的有限公司) 呈交日期: 2026年1月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02189 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 3,000,000,000 | HKD | | 0.01 HKD | | | 30,000,000 | | 增加 / 減少 (-) | | | | | | HKD | | | | | 本月底結存 | | | 3,000,000,000 | HKD | | 0.01 HKD | | ...

Nursing Home Operations - As of September 30, 2025, the group operates 12 nursing homes with a total of 1,556 beds, an increase from 1,378 beds as of March 31, 2025[7]. - The average monthly occupancy rate for the group as of September 30, 2025, is 92.3%, up from 91.5% as of March 31, 2025[11]. - The occupancy rates for individual nursing homes include 99.1% for Kato Elderly Home and 99.2% for Kato Elderly Health Home as of September 30, 2025[11]. - The group has expanded its nursing home network strategically across six regions in Hong Kong, maintaining a consistent presence in these areas[7]. - The group has recently upgraded the Tuen Mun branch of Fai To Nursing Home to a Class A nursing home as of May 2025[10]. - The group has contracts with the Social Welfare Department for the purchase of beds under the Enhanced Buy-Place Scheme, catering to both subsidized and self-paying clients[8]. - The total number of beds under the Enhanced Buy-Place Scheme is 850, while the remaining 706 beds are classified as non-enhanced[9]. - The group has a total of 178 beds available in the two new nursing homes, which began operations in mid-2024[18]. - The new nursing home in Tsuen Wan with 192 beds began operations in August 2025, and a second phase with 146 beds in Lam Tin is expected to start operations in November 2025[38]. - The group has become an approved service provider under the Guangdong Elderly Care Service Program, offering subsidized nursing home beds in Shenzhen and Foshan[39]. Financial Performance - Revenue increased from approximately HKD 148.0 million in the previous period to approximately HKD 174.2 million in the current period, primarily due to the full operation of two nursing homes starting in June and September 2024 and an increase in average occupancy rates[17]. - The total revenue breakdown for the six months ending September 30, 2025, includes: HKD 73.1 million (42.0%) from government-subsidized nursing home services, HKD 58.6 million (33.6%) from private customer purchases, and HKD 30.2 million (17.3%) from related product sales[16]. - Profit for the current period increased by approximately 7.3% to about HKD 27.4 million from approximately HKD 25.5 million in the previous period[20]. - Revenue for the six months ended September 30, 2025, was HKD 174,249,000, an increase of 17.8% compared to HKD 147,971,000 for the same period in 2024[57]. - The company reported a pre-tax profit of HKD 26,976,000 for the six months ended September 30, 2025, compared to HKD 25,664,000 for the same period in 2024, reflecting a growth of approximately 5%[63]. - The group reported a pre-tax profit of HKD 32.481 million for the six months ended September 30, 2025, compared to HKD 30.257 million for the same period in 2024, reflecting an increase of approximately 7.4%[85][86]. Expenses and Liabilities - Employee benefits expenses rose from approximately HKD 58.5 million to approximately HKD 71.1 million, mainly due to the increased workforce at the two new nursing homes[18]. - Food and beverage costs increased to approximately HKD 7.3 million from approximately HKD 6.3 million, attributed to the full operation of the new nursing homes and higher average occupancy rates[19]. - The total liabilities as of September 30, 2025, amounted to HKD 366.654 million, compared to HKD 418.278 million as of March 31, 2025, indicating a decrease of approximately 12.3%[80]. - The total amount of trade and other payables was HKD 29,847 as of September 30, 2025, a decrease from HKD 30,977 as of March 31, 2025[116]. - The total liabilities related to leases decreased to HKD 108,579 as of September 30, 2025, from HKD 125,189 as of March 31, 2025[101]. Assets and Equity - As of September 30, 2025, the net asset value of the group was approximately HKD 451.7 million, up from approximately HKD 442.2 million as of March 31, 2025[22]. - The debt-to-equity ratio as of September 30, 2025, was 54.2%, down from 60.9% as of March 31, 2025[24]. - The group’s bank borrowings amounted to HKD 193.2 million as of September 30, 2025, with a floating interest rate[25]. - The company's total equity as of September 30, 2025, was HKD 443,727,000, up from HKD 440,894,000 as of March 31, 2025, indicating a slight increase of about 0.6%[63]. - Total assets as of September 30, 2025, amounted to HKD 791,443,000, a decrease from HKD 809,566,000 as of March 31, 2025[60]. Corporate Governance - The company maintained compliance with corporate governance codes, with a noted deviation regarding the roles of the Chairman and CEO being held by the same individual[54]. - The Audit Committee, consisting of three independent non-executive directors, reviewed the unaudited financial statements for the period[55]. - The company continues to focus on maintaining high levels of corporate governance to protect shareholder interests[54]. - The company has adopted a code of conduct for directors' securities trading, confirming compliance with the standard code during the reporting period[48]. Shareholder Information - As of September 30, 2025, the company has a total issued share capital of 1,000,000,000 shares[45]. - The major shareholder, Shangfeng, holds 626,096,000 shares, representing 62.61% of the total issued shares[45]. - Wei Xiaoling, a significant stakeholder, has a total of 647,604,000 shares, accounting for 64.76% of the total issued shares[45]. - The company did not declare an interim dividend for the six months ended September 30, 2025, consistent with the previous year[96]. Cash Flow and Investments - Cash generated from operating activities for the six months ended September 30, 2025, was HKD 59,880,000, compared to HKD 55,429,000 for the same period in 2024, reflecting an increase of approximately 8.8%[65]. - The company incurred capital expenditures of HKD 9,359,000 during the reporting period, which is an increase from HKD 6,136,000 in the previous year[65]. - The net cash used in investing activities for the six months ended September 30, 2025, was HKD 9,955,000, a significant decrease from HKD 22,840,000 in the same period of 2024[65]. - The company completed the acquisition of a subsidiary, resulting in a cash outflow of HKD 1,940,000 during the reporting period[65]. Employee Compensation - The total employee benefits expenditure for the period is approximately HKD 71.1 million, an increase from HKD 58.5 million in the previous period[36]. - The total compensation for key management personnel increased to HKD 4,404 for the six months ended September 30, 2025, compared to HKD 4,834 in the previous year[114].

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年11月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 嘉濤（香港）控股有限公司 (於開曼群島註冊成立的有限公司) 呈交日期: 2025年12月1日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02189 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 3,000,000,000 | HKD | | 0.01 HKD | | 30,000,000 | | 增加 / 減少 (-) | | | | | | HKD | | | | 本月底結存 | | | 3,000,000,000 | HKD | | 0.01 HKD | | 30,000,000 | 本 ...

Core Viewpoint - 嘉涛(香港)控股 reported a total revenue of approximately HKD 174 million for the six months ending September 30, 2025, representing an increase of about 17.8% compared to the same period in 2024 [1] - The profit attributable to the company's owners was approximately HKD 27 million, reflecting a year-on-year increase of about 5.1% [1] - The board of directors did not recommend the payment of an interim dividend for the six months ending September 30, 2025, consistent with the previous period where no dividend was declared [1] Financial Performance - Total revenue for the six months ending September 30, 2025, was approximately HKD 174 million, up 17.8% from the previous year [1] - Profit attributable to owners was approximately HKD 27 million, an increase of 5.1% year-on-year [1] - No interim dividend was proposed for the current period, maintaining the same stance as the previous year [1] Business Development - In 2022, the company expanded into the medical diagnostics and health check market in Hong Kong [1] - The company offers a variety of healthcare services, including general health checks, X-rays, ECGs, mammograms, ultrasounds, DEXA bone density tests, and various laboratory tests [1] - As of March 31, 2025, the company operated three medical health check centers in three regions of Hong Kong [1] - The company terminated its medical and laboratory services in April 2025 to focus resources on developing elderly care services [1]